|
CN111926039A
|
|
Construction method and application of IL-13 gene humanized non-human animal
|
|
CN111926038A
|
|
Construction method and application of CSF2RB gene humanized modified non-human animal
|
|
CN111793647A
|
|
Construction method and application of CD226 gene humanized non-human animal
|
|
CN111793648A
|
|
Construction method and application of ETAR gene humanized and transformed non-human animal
|
|
CN111789954A
|
|
Method and medicament for delaying senility
|
|
CN111793646A
|
|
Construction method and application of non-human animal subjected to IL1R1 gene humanization transformation
|
|
CN111763259A
|
|
anti-CD 40 antibodies and uses thereof
|
|
CN112048522A
|
|
Construction method and application of TMEM173 gene humanized and modified animal model
|
|
CN111763257A
|
|
anti-GITR antibodies and uses thereof
|
|
CN111763258A
|
|
anti-OX 40 antibodies and uses thereof
|
|
CN111808882A
|
|
Construction method and application of IL7R gene humanized modified animal model
|
|
CN111808196A
|
|
anti-PD-1 antibodies and uses thereof
|
|
CN111705085A
|
|
Method for constructing animal model and application
|
|
WO2021018198A1
|
|
Genetically modified non-human animal with human or chimeric il33
|
|
WO2020169022A1
|
|
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
CN111218425A
|
|
Humanized transgenic animal
|
|
WO2020103885A1
|
|
Anti-pd-1 antibodies and uses thereof
|
|
CN111197058A
|
|
Preparation method and application of humanized CD73 gene animal model
|
|
CN111057721A
|
|
Preparation method and application of humanized IL-4 and/or IL-4R α modified animal model
|
|
WO2020001344A1
|
|
ANTI-CD3e ANTIBODIES AND USES THEREOF
|
